Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

96.75 -1.41 (-1.44%)
Streaming Delayed Price Updated: 1:43 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
58 59 Next >
Gilead Sciences Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Biotech And Life Science Sector Update Summer Of 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
Via Benzinga
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process. 
Via Investor's Business Daily
Exposures Product Safety
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts
Via Benzinga
Biotech Bull Market: 3 Ways To Play It
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Gilead's Ongoing Battle Against Counterfeit HIV Medications Persists With New Lawsuit, Seizes $750K In Fake Drugs
Gilead Sciences exposes a major counterfeiting ring led by Peter Khaim, involving tampered HIV medications resold from New York pharmacies. The company seized over $750K in fake drugs, intensifying its... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
FDA grants accelerated approval to Gilead's Livdelzi (seladelpar) for primary biliary cholangitis, offering new treatment options for patients with inadequate response to standard therapy. Continued... 
Via Benzinga
Exposures Product Safety
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
From Gilead Sciences, Inc.
Via Business Wire
Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat
The company retained its full-year outlook for product sales. 
Via Investor's Business Daily
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Gilead Sciences's Options Frenzy: What You Need to Know
Via Benzinga
7 Defensive Stocks to Buy as Investors Seek Shelter
With the market primed for more jitters, investors should consider battening down the hatches with these defensive stocks. 
Via InvestorPlace
3 Stocks Retirees Should Absolutely Love
All of these stocks can provide steady income to retired investors. 
Via The Motley Fool
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
Gilead Sciences' Q2 2024 revenue rose to $6.95B, beating expectations, driven by strong performance in HIV, Liver Disease, and Oncology. Adjusted EPS surged to $2.01, surpassing estimates, supported by... 
Via Benzinga
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
After a blistering Thursday that saw the S&P 500 close with its best session in nearly two years — up 2.3% — Wall Street’s price action turned sluggish on a Friday lacking market-moving economic... 
Via Benzinga
Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript
GILD earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q2 2024
GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Gilead Sciences Announces Second Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Wall Street Set For Uneventful Start Ahead Of Jobless Claim Data, VIX Rises: Strategist Says Market May Remain Vulnerable Until...
U.S. stocks are set for a mixed start on Thursday as concerns regarding the economy and incremental yen carry trade unwinding remain an undercurrent. Traders may be keen to receive the jobless claims... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday?
Investor risk sentiment is showing greater conviction on Thursday, with all indices and major stock sectors in the green, after Wall Street failed to hold onto opening gains and closed in the red the... 
Via Benzinga
Four Stocks To Watch This Week - Monday, August 5
The unease we've been mentioning over the past several weeks has borne bearish fruit in the last two weeks. The good news is that stocks are correcting across the board, which means they will... 
Via Talk Markets
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
Dividend stocks are great; cheap dividend stocks are better. 
Via The Motley Fool
Q3’s Rising Stars: 3 Nasdaq Stocks for Your Must-Watch List
Traders are rushing out of overvalued and overhyped Nasdaq stocks, making it a great time to rotate into these Nasdaq stocks to watch. 
Via InvestorPlace
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Stock Whisper Index provides a weekly list of five stocks that are seeing above-average interest from readers. 
Via Benzinga
The Top 3 Biotech Stocks to Buy Now Summer 2024
These biotech stocks are well-positioned to generate high returns for investors due to their significant growth prospects. 
Via InvestorPlace
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.